ClinicalTrials.gg
Enrolling by invitationNCT06919133MENTINAUpdated Jan 14, 2026

The Effect of Digital Markers in the Self-management of Depressive Symptoms

An interventional study of The MENTINA app and Control in Depression - Major Depressive Disorder and Mental Distress, sponsored by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital. Enrolling by invitation at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Depression with a site in Denmark — 14 open to participants now, 17 under way, none of them phase 3. Depression · Denmark.

Planned enrollment
10th of 92
660 · median 139
Started
2025
with 11 others
No phase
69 of 124
9 open now
Primary completion
2027-05
later than 10 of 16 live
Registered
116th of 124
by date
Lead sponsor
5 of 124
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital

Among the 124 studies in Depression with a site in Denmark, this one is the 10th largest by planned enrollment of the 92 interventional ones that give a count, is one of 12 that started in 2025, is one of 69 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 116th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

14 of the 124 studies in Depression with a site in Denmark are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Depression with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of the MENTINA trial is to investigate the effect of using the smartphone-based MENTINA app for self-monitoring of depressive symptoms and rule-based feedback in individuals with current or previous depression, psychological vulnerability, and increased risk of depression in a randomized controlled trial (RCT) over a 12-month trial period. The aim is to potentially offer the MENTINA app as a self-management tool for individuals with psychological vulnerability and/or depressive symptoms or episodes.

Method and Design:

International, multicenter (three centers), parallel-group, RCT. The active group is assigned the smartphone-based MENTINA app including rule-based data feedback. The control group uses the MENTINA app for questionnaire-based data collection (outcomes) and collection of sensor-based data.

Study Procedures:

The trial will be open-label and unblinded. The trial uses the self-reported Patient Health Questionnaire-9 score (PHQ-9) as the primary outcome measure. Scoring will take place every 14 days over the 12-month trial period. Depressive symptoms during the first 6 months of app use will also be evaluated as secondary outcomes.

Participants, Including Inclusion and Exclusion Criteria A total of 220 individuals will be included from each center (Denmark, Germany, and Spain) with psychological vulnerability (depressive symptoms and possibly previous depressive episodes). A total sample size of 660 participants will be included.

Inclusion criteria:

  • Age 18 years or older
  • Depressive symptoms, assessed by PHQ-9 > 8, AND/OR
  • Current or previous depressive episode(s) (ICD-10 F32, F33)
  • Owns and uses a smartphone
  • Signed informed consent to participate

Exclusion criteria:

  • ICD-10 diagnosis of dementia, schizophrenia, mania, or bipolar disorder, as well as ongoing substance abuse
  • Current psychotic depression
  • Current suicide risk
  • Acute somatic illness requiring treatment (intensive care)
  • Insufficient language skills in Danish, German or Spanish (depending on site)

Side Effects, Risks, and Disadvantages

Side effects and risks:

We do not expect any serious side effects from using the MENTINA app. Possible side effects could include increased focus on one's own illness, potentially worsening depressive symptoms and suicidal thoughts.

Recruitment of Participants The study population will consist of adults vulnerable to mental health issues, defined by a PHQ-9 score > 8 or previous depressive symptoms at the time of inclusion. Each study site will be responsible for local recruitment and follow-up.

Read the detailed description

The intervention in the MENTINA trial consist of a smartphone app, which allows for daily monitoirng of symptoms such as mood, sleep, activity etc. Also, a library with content concerning depressive symptoms will be available.

Rules for feedback based of self-reported measures will be developed. Based on the self-reported measures participants will be suggested to read items from the library or call emergency health care facilities.

03

Conditions studied

  • Depression - Major Depressive Disorder
  • Mental Distress

Browse trials for

Keywords

  • Depression
  • Mental distress
  • Smartphone
  • Trial
  • self-management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Depressive symptoms, assessed by PHQ-9 > 8, AND/OR
  • Current or previous depressive episode(s) (ICD-10 F32, F33)
  • Owns and uses a smartphone
  • Signed to participate

Exclusion criteria

Exclusion Criteria:

  • ICD-10 diagnosis of dementia, schizophrenia, mania, or bipolar disorder, as well as ongoing substance abuse
  • Current psychotic depression
  • Current suicide risk
  • Acute somatic illness requiring treatment (intensive care)
  • Insufficient language skills in Danish, German or Spanish and english (depending on site)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
660 participants (estimated)

Study arms

  • Experimental
    Smartphone-based self-monitoring and rule-based feedback

    The smartphone-based MENTINA app for daily self-monitoring of depressive symptoms and other symptoms + rule-based feedback based on self-monitoried data and sensor data from smartphones

    Device: The MENTINA app

  • Placebo comparator
    Control

    The app is installed for outcome measures, but no access to the content of the app is provided.

    Other: Control

Interventions

  • DeviceThe MENTINA app

    A smartphone-based app is developed and used in this trial. The smartphone-based MENTINA app allows for daily self-monitoring of depressive symptoms such as mood, sleep, activity etc and rule-based feedback based on self-monitored data as well as collected sensor data. Libary with relevant content will also be available and incoorporated in the rule-based feedback.

  • OtherControl

    The MENTINA app is installed but no content and self-monitoring is available. No rule-based feedback. Only outcome measures can be done.

06

What researchers measure

Primary outcomes

  1. Patient Health Questionnaire 9 items (PHQ-9)

    Differences between the intervention group and the control group in the total Patient Health Questionnaire 9 items (PHQ-9) score performed every 14th day during the 12-months trial period.

    Time frame: From enrollment and during the study period of 12 months

Secondary outcomes

  1. Quality of Life

    Differences between the intervention group and the control group in the level of quality of life according to the WHO Quality of life BREF16 (WHO QoL)

    Time frame: From enrollmetn to end of treatment af 12 months

  2. Generalized Anxiety Disorder 7 items scale (GAD-7)

    Differences between the intervention group and the control group in the level of anxiety symptoms according to the Generalized Anxiety Disorder scale (GAD-7)

    Time frame: From enrollment to end of treatment at 12 months

  3. PHQ-9

    * Monthly change in PHQ-9 scores * Response rate defined as the proportion of participants with ≥50% reduction in PHQ-9 * Remission rate defined as PHQ-9 ≤9 and ≥5-point improvement * PHQ-9 scores at 6 months * Area Under the Curve (AUC) for PHQ-9 over the trial period * Subgroup analysis: differences between the two groups in PHQ-9 analyzed separately for: * People with mental distress (without lifetime depression) * People with a lifetime diagnosis of depression

    Time frame: From baseline and during the 12 months study period

  4. Perceived Stress Scale (PSS)

    Differences between the group

    Time frame: From baseline and during the 12 months study period

  5. User-reported healthcare contacts

    Number of healthcare contact during the study

    Time frame: From baseline and during the 12 months study period

  6. Negative effects: Negative Effects Questionnaire (NEQ)

    Differences between the two groups

    Time frame: Form baseline and during the 12 months study period

  7. PHQ-9

    * Number of depressive episodes (based on PHQ-9) * Duration * Number of depression-free days (based on PHQ-9)

    Time frame: From baseline and during the 12 months study period

Other outcomes

  1. Usability of the app: System Usability Scale (SUS)

    Usability of the app: System Usability Scale (SUS)

    Time frame: From baseline and during the study period

  2. Perceived usefulness for patient-clinician communication

    Qualitative interviews

    Time frame: From baseline and during the trial period

  3. Interviews with participants and clinicians/psychotherapists

    Qualitative interviews on an subsample

    Time frame: From baseline and during the trial period

07

Study locations

3 sites
08

References and documents

Publications

  • Faurholt-Jepsen M, Dyreholt MS, Kyster NB, Iversen N, Kortsen EM, Amann BL, Hogg B, Gatto D, Cordoba C, Petrovic M, Allenhof C, Schnitzspahn K, Reich H, Budtz-Jorgensen E, Kessing LV, Hegerl U. Effect of digital intervention in the self-management of depressive symptoms: the MENTINA trial - a study protocol for a randomised controlled parallel-group trial. BMJ Open. 2026 Feb 4;16(2):e115773. doi: 10.1136/bmjopen-2025-115773. PubMed 41638726 ↗

Individual participant data

Plan to share: No — Sensitive data that cannot be anonymised completely.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 23 months is close to that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2025
First posted
Apr 9, 2025
StartActual
May 13, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06919133
Lead sponsor
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Collaborators
Hospital del Mar Research Institute (IMIM), Research Centre of the German Foundation for Depression and Suicide Prevention, Monsenso, Monsenso A/S as sponsor
Responsible party
Lars Vedel Kessing (Professor, MD, Dr.Med., Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital) — Principal investigator
First posted
Apr 9, 2025
Start date
May 13, 2025
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jan 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion